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We demonstrate how direct, indirect, total, and overall effectiveness estimates and absolute benefits of rotavirus
vaccines vary through the years following vaccine introduction. Privately insured US children in a large claims
database were followed from age 8 months until they 1) experienced a hospitalization for rotavirus or acute gastro-
enteritis; 2) lost continuous health plan enrollment; 3) turned 20 months of age; or 4) reached the end of the study
period. Vaccine effectiveness estimates in preventing rotavirus and acute gastroenteritis hospitalizations were es-
timated using Cox proportional hazards regression, stratified by calendar year and adjusted for birth month. Inci-
dence rate differences were estimated to determine the absolute number of gastroenteritis hospitalizations
prevented in the cohort. Among 905,718 children, 51%, 66%, 80%, and 86% received 1 or more doses of rotavirus
vaccine in each year from 2007 to 2010. The direct vaccine effectiveness of 1 or more doses of rotavirus vaccine in
preventing rotavirus gastroenteritis hospitalizations ranged from 87% to 92% each year. Accounting for indirect pro-
tection increased estimates of vaccine effectiveness by an additional 3%–8% among those vaccinated. Failing to
account for population-level vaccine benefits in 2010, when circulation of rotavirus was low, could underestimate the
sustained impact of the vaccine program.
diarrhea; gastroenteritis; immunity, herd; pharmacoepidemiology; program effectiveness; rotavirus; rotavirus
vaccines; use-effectiveness
Abbreviations: AGE, acute gastroenteritis; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification;
IRD, incidence rate difference; RGE, rotavirus gastroenteritis; RV1, rotavirus monovalent vaccine; RV5, rotavirus pentavalent
vaccine; VE, vaccine effectiveness.
Most phase III vaccine efficacy trials determine the direct
vaccine effectiveness (VE), generally measured as 1 minus
the relative risk in the vaccinated group compared with the un-
vaccinated group. Some clinical trials and many postlicensure
studies also measure herd protection, or indirect VE, defined as
population-level effects of widespread vaccination on people
not receiving the vaccine (1). Two additional population-level
measures of VE, total and overall VE, account for both the di-
rect and indirect effectiveness of a vaccine (Figure 1). Total VE
combines the direct and indirect VE on individuals receiving
the vaccine, whereas the overall VE weights the average of
the total VE on individuals receiving the vaccine with the in-
direct VE on individuals not receiving the vaccine (1). Total
VE can thus be interpreted as the complete benefit of vaccina-
tion in vaccine recipients, and overall VE can be interpreted as
the public health benefit of vaccination. Despite challenges in
estimating the 4 types of VE, they are essential to understand-
ing the real-world impact of a vaccine (1–3).
Rotavirus was the leading cause of gastroenteritis in in-
fants and young children, implicated in 55,000–70,000 hos-
pitalizations in the United States prior to the availability of a
rotavirus vaccine (4). Rotavirus vaccination is currently
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recommended by the Centers for Disease Control and Pre-
vention (Atlanta, Georgia), and 2 vaccines are marketed in
the United States (5). The pentavalent rotavirus vaccine
(RV5), RotaTeq (Merck & Co., Inc., Whitehouse Station,
New Jersey), administered orally in 3 doses at ages 2, 4,
and 6 months, has been licensed since February 2006, and
the monovalent rotavirus vaccine (RV1), Rotarix (Glaxo-
SmithKline Biologics, Research Triangle Park, North Caro-
lina), administered orally in 2 doses at ages 2 months and 4
months, has been licensed since April 2008.
We compared direct, indirect, total, and overall rotavirus
VE estimates for the prevention of rotavirus gastroenteritis
(RGE) and acute gastroenteritis (AGE) hospitalizations
from 2007 to 2010 to determine how these 4 VE estimates
varied through the years after vaccine introduction. We also
examined how the absolute number of gastroenteritis hospi-
talizations varied through the years.
METHODS
Data source
The MarketScan Research Databases (Truven Health An-
alytics, Inc., Ann Arbor, Michigan) contain data from more
than 111 million individuals throughout the United States
with commercial health insurance. In 2010, the database in-
cluded approximately 920,000 infants, corresponding to ap-
proximately 25% of the US birth cohort and 50% of the US
birth cohort with commercial insurance (6, 7).
Design and population
Data on infants with continuous insurance enrollment dur-
ing infancy, at least 1 outpatient claim for any service or
diagnosis, and an International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM), code for
a livebirth between May 1, 2000, and April 30, 2005, or May
1, 2006, and April 30, 2010, were extracted from the data-
bases (Table 1). If an infant or mother had a claim for a live-
birth on multiple dates within a short period of time, the date
of the first claim was used as the birth date. Follow-up for
RGE began when infants turned 8 months of age and contin-
ued until a maximum age of 20 months. Infants younger than
8 months and infants receiving doses of rotavirus vaccine
after 8 months were excluded so that rotavirus vaccine status
could be treated as a single point exposure.
Infants with commercial insurance who failed to receive
vaccines with high coverage rates (≥95%) may differ from
infants receiving such vaccines with respect to unmeasured
confounding factors, so we required all infants in our study
to be vaccinated with at least 1 dose of diphtheria, tetanus,
and acellular pertussis vaccine using Current Procedural Ter-
minology codes (8).
Outcome, exposure, and covariate measurements
Outcomes of RGE and AGE were identified using ICD-9-
CM codes. Any of the 15 diagnosis fields in the inpatient files
of the databases was used to capture the ICD-9-CM code
008.61 for gastroenteritis due to rotavirus. Rotavirus-coded
events underestimate the true burden of rotavirus disease be-
cause of lack of routine laboratory testing and coding; there-
fore, we performed sensitivity analyses, assuming 25% and
50% sensitivity of the 008.61 code (9, 10), and extracted
and examined outcomes related to AGE (11–13). Emergency
department and outpatient visits for RGE and AGE were not
included in the analysis.
2. Vaccinated population
(after introduction of vaccine)
2A. Hazard   
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VE = (1 – 2A / 1A) x 100
VE = (1 – 2B / 1A) x 100
VE = (1– (2A,2B) / 1A) x 100
VE = (1 – 2B / 2A) x 100
Figure 1. Types of vaccine effectiveness as described by Halloran et al. (1). A vaccinated population will still have some individuals within the
population who are unvaccinated because 100% vaccination coverage is generally never achieved. VE, vaccine effectiveness.
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RV5 and RV1 vaccination status at 8 months of age was
classified using the Current Procedural Terminology codes
90680 and 90681. To increase the sensitivity of vaccination
status, we excluded infants living in states with state-funded
rotavirus immunization programs (Alaska, Idaho, Massachu-
setts, Maine, North Dakota, New Hampshire, New Mexico,
Oregon, Rhode Island, Vermont, Washington, Wisconsin,
and Wyoming) (13).
To account for household-level variation in rotavirus vac-
cine coverage, disease, and mixing behaviors, we examined
the number of other dependent children less than 10 years of
age covered by the same insurance holder as the infant (con-
sidered to be older siblings). To account for geographical var-
iation, we included the region and rurality of the child’s
residence, as defined by the US Department of Agriculture,
Economic Research Service (14). To characterize general in-
fant health and potential differences in susceptibility to rota-
virus disease, we compared the percentage of infants who had
overnight hospital stays unrelated to AGE prior to 2 months
of age.
Data analysis
We used Cox proportional hazard regression models to es-
timate hazard ratios, comparing the hazard of RGE or AGE
hospitalization among vaccinated infants to that among
unvaccinated infants entering the cohort in 2007, 2008,
2009, or 2010 and subtracting the result from 1 to obtain es-
timates of direct VE by calendar year. We similarly estimated
the indirect, total, and overall VE, varying the comparison
cohorts accordingly. For indirect VE, we compared unvacci-
nated infants followed during each calendar year of the rota-
virus vaccine period, 2007–2010, with (unvaccinated) infants
followed during the baseline period, 2001–2005. For total
VE, we compared vaccinated infants followed during each
calendar year of the rotavirus vaccine period with (unvac-
cinated) infants followed during the baseline period. For
overall or average VE, we compared all vaccinated and un-
vaccinated infants during each calendar year of the rotavirus
vaccine period with (unvaccinated) infants followed during
the baseline period.
In all regression analyses, age served as the underlying
time scale, and infants were censored when they experienced
a RGE or AGE hospitalization, lost continuous enrollment,
reached 20 months of age, or reached the end of the study pe-
riod on December 31, 2005, or December 31, 2010, which-
ever occurred first. Results were stratified by year to account
for increasing vaccination coverage and possible variations
in rotavirus transmission by year and adjusted for month
of birth to account for the seasonality of rotavirus. Infants
and children were allowed to contribute person-time during
2 calendar years. For example, an infant who turned 8months
of age on October 1, 2007, would contribute up to 3 person-
months in 2007 and reenter the cohort on January 1, 2008,
at age 11 months, to contribute up to 9 more calendar
months of person-time in 2008. Infants followed during
2 calendar years in the baseline period were followed
continuously.
We estimated incidence rate differences (IRDs) on the basis
of the case count and person-years in the population and per-
formed additional analyses assuming 25% and 50% sensitiv-
ity and 100% specificity of the RGE and AGE ICD-9-CM
codes to determine the absolute number of RGE and AGE
hospitalizations prevented by the rotavirus vaccine program
in the cohort.
All analyses were conducted in SAS, version, 9.2, software
(SAS Institute, Inc., Cary, North Carolina). This study was
exempt from human subjects review by the institutional re-
view board of the University of North Carolina at Chapel
Hill (Chapel Hill, North Carolina).
RESULTS
Cohort
Approximately half (52%) of the 3.94 million infants iden-
tified in the enrollment files between January 2000 and De-
cember 2010 had a claim for a livebirth (Figure 2). After
additional exclusions, 627,818 (78%) of the 905,718 children
in the final cohort were born during the rotavirus vaccine pe-
riod (476,576 were vaccinated with a rotavirus vaccine;
151,242 were unvaccinated). The other 277,900 children
were born during the prevaccine baseline period. Among
all 627,818 children followed during the rotavirus vaccine
period, 379,262 (60%) were followed during parts of 2 calen-
dar years.
Table 1. ICD-9-CM and CPT Codes Used in Analyses of US
Commercially Insured Infants and Children 8–20 Months of Age
(11–13)





DTaP vaccine or related
vaccines, including
combinations
90696, 90698, 90700, 90701,
90702, 90714, 90715,







Bacterial 001–005 (excluding 003.2),
008.0–008.5












Abbreviations: CPT, Current Procedural Terminology; DTaP, diph-
theria, tetanus, acellular pertussis vaccine; ICD-9-CM, International
Classification of Diseases, Ninth Revision, Clinical Modification;
RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus
vaccine.
Effectiveness of Rotavirus Vaccines in US Children 897
Am J Epidemiol. 2014;179(7):895–909
Characteristics of the cohort
Almost 76% of the children born during the rotavirus vac-
cine period received at least 1 dose of RV5 or RV1, of which
79% completed the series. Vaccination rates varied by calen-
dar year, ranging from 51% in 2007 to 86% in 2010. Most
vaccinated children (91%) received RV5, and more than
3% received doses of RV5 and RV1. The vaccinated and un-
vaccinated children were generally comparable (Table 2);
however, children residing in the Western United States
were better represented during the baseline years than in
the vaccine years (19% vs. 11%).
RGE hospitalizations
The number of infants and children in the cohort hospital-
ized with RGE during follow-up was 1,016 (0.11%). The
percentage of infants and children hospitalized for RGE de-
creased during each calendar period as follows: for 2001–
2005, 722/277,899 (0.26%); for 2007, 63/133,309 (0.05%);
for 2008, 114/266,941 (0.04%); for 2009, 96/311,253
(0.03%); and for 2010, 21/296,323 (0.01%). The incidence
rate of RGE hospitalization in March, the traditional peak
of rotavirus activity, ranged from 121 per 10,000 child-years
(95% confidence interval (CI): 106, 137) during the prevac-
cine period to 1 per 10,000 child-years (95% CI: 0, 5) in 2010
(Figure 3).
AGE hospitalizations
Compared with the prevaccine period, the proportions of
children hospitalized annually for gastroenteritis during the
rotavirus vaccine period were generally consistent for viral
(excluding rotavirus), bacterial, and presumed infectious
Enrollment Files, 
2000–2010 
n = 3,944,154 
Continuous Enrollment Throughout Infancy 
n = 994,022 
Born May 2000–April 2005 or May 2006–April 2010 
n = 1,605,578 
Resident of State Without State-Funded Rotavirus Vaccination Programs 
n = 905,718 
Mother/Infant Inpatient and Outpatient Files, 
2000–2010 
n = 2,073,467 
Outpatient Files, 
2000–2010 
n = 3,484,370 
n = 2,024,210 
Did Not Receive Any Doses of RV5 or RV1 After Age 8 Months 
n = 1,311,423 
No Missing Covariates 
n = 905,718 
Unvaccinated Infants 
n = 151,242 
Unvaccinated Population, 2001–2005 
n = 277,900 
Vaccinated Population, 2007–2010 
n = 627,818 
Vaccinated Infants 
n = 476,576 
Received DTaP Vaccine 
n = 1,322,652 
n = 2,056,442 
Population 1 Population 2 
Unvaccinated Infants 
n = 277,900 
Figure 2. Derivation of the unvaccinated population (population 1) and the vaccinated population (population 2) in the rotavirus vaccine effectiveness
cohort study of US commercially insured infants and children 8–20 months of age, 2001–2005 and 2007–2010. Births were identified using Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modification, codes in inpatient and outpatient records. These records were restricted to
infants 0 years of age and to females 10–50 years of age. Twenty-three of 905,718 infants were excluded from this cohort in the final rotavirus gas-
troenteritis analysis because their cohort entry date (8-month birthday) equaled their cohort exit date (rotavirus gastroenteritis hospitalization date
(n = 4) or loss of health plan enrollment date (n = 19)); for the same reasons, 40 infants were excluded from the final acute gastroenteritis analysis.
DTaP, diphtheria, tetanus, and acellular pertussis vaccine; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine.
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Male 51.6 50.9 51.4 50.9 51.4 51.1 51.6 51.3 52.0
Hospitalized overnight for
non-AGE (before
2 months of age)
3.9 4.0 4.0 3.9 4.0 3.6 4.0 3.5 4.0
No. of siblings 0.9 (1.0)b 0.8 (1.0)b 0.9 (1.0)b 0.8 (1.0)b 0.9 (1.0)b 0.8 (1.0)b 0.9 (1.1)b 0.8 (1.0)b 0.9 (1.1)b
US region of residence
Northeast 10.4 6.9 9.4 8.4 10.9 11.4 16.7 13.9 22.0
North central 24.4 31.1 34.6 30.0 34.4 28.4 31.1 27.9 26.8
South 46.0 53.5 43.9 52.3 41.9 50.3 39.3 46.2 37.2
West 19.1 8.5 12.1 9.3 12.8 10.0 13.0 12.0 14.1
Population density of
residence
Metro with ≥1 million
population
57.7 56.5 58.7 58.1 57.3 60.3 58.0 61.4 59.8
Metro with 250,000–1
million population
19.6 19.3 16.6 19.1 16.8 18.2 15.8 18.6 16.2
Metro with <250,000
population




3.8 3.8 4.1 3.6 4.1 3.4 4.2 3.3 4.0
Urban with ≥20,000
population, not
adjacent to metro area




4.3 4.0 4.9 4.1 5.3 3.9 5.4 3.6 4.9
Urban with 2,500–19,999
population, not
adjacent to metro area




0.6 0.6 0.6 0.5 0.6 0.5 0.6 0.5 0.4
Rural with <2,500
population, not
adjacent to metro area
0.5 0.4 0.5 0.5 0.6 0.4 0.7 0.4 0.6
Abbreviations: AGE, acute gastroenteritis; metro, metropolitan; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine.
a A total of 379,262 (60%) infants and children were counted during 2 consecutive calendar years during the vaccine period, 2007–2010.

























































gastroenteritis, as well as for diarrhea from other causes, but
decreased for rotavirus (as expected) and noninfectious diar-
rhea (Figure 4). Overall, the number of infants and children in
the cohort with an AGE diagnosis was 4,483 (0.49%). The
percentage of infants and children hospitalized for AGE dur-
ing the prevaccine years was 0.73% (2,021/277,893). This
percentage declined to 0.31% (413/133,306) in 2007 and
continued to decline steadily during the vaccine years, reach-
ing 0.17% (507/296,120) in 2010. Overall, nearly 1 quarter
of the AGE diagnoses were coded as RGE. However, the pro-
portion of children with AGE diagnostic codes that corre-
sponded to RGE generally decreased with each successive
calendar period (for 2001–2005, 36% (722/2,021); for
2007, 15% (63/413); for 2008, 16% (114/730); for 2009,
12% (96/812); and for 2010, 4% (21/507)). Despite the de-
cline in the proportion of AGE diagnoses coded as RGE
through the years, the monthly incidence rate of AGE by
year followed a similar pattern as the monthly incidence
rate of RGE by year (Figure 5).
Rotavirus VE
Direct VE of 1 or more doses of RV5 or RV1 in preventing























































































Figure 3. A) Incidence of rotavirus gastroenteritis (RGE) hospitalizations per 10,000 child-years among commercially insured US infants and chil-
dren 8–20 months of age, individual years following vaccine introduction (2007–2010) versus prevaccine years combined (2001–2005). Solid line,
2001–2005; dashed and dotted line, 2007; small dashed line, 2008; large dashed line, 2009; dotted line, 2010. B) Incidence of RGE hospitalizations
per 10,000 child-years among commercially insured US infants and children 8–20 months of age, individual prevaccine years (2001–2005). Solid
line, 2001; dashed and dotted line, 2002; small dashed line, 2003; large dashed line, 2004; dotted line, 2005.
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from 87% (95% CI: 58%, 92%) in 2007 and 87% (95% CI:
80%, 92%) in 2008 to 92% (95% CI: 87%, 95%) in 2009
(Table 3). The indirect VE varied more widely, from 14%
(95% CI: −14%, 36%) in 2007 to 82% (95% CI: 70%,
90%) in 2010. Accounting for both direct and indirect VE
among the rotavirus-vaccinated infants yielded a total VE es-
timate that increased from 91% (95% CI: 73%, 97%) in 2007
to 98% (95% CI: 96%, 99%) in 2010. The overall VE ranged
from 40% (95% CI: 20%, 54%) in 2007 to 96% (95% CI:
93%, 97%) in 2010. The overall VE estimate was low in
2007 compared with that in 2008–2010, but the direct and
total VE estimates were high (≥87%) across all 4 calendar
years. The rotavirus VE estimates were substantially lower
in the prevention of AGE hospitalization, but generally fol-
lowed a similar pattern to the VE estimates in the prevention
of RGE hospitalization (Table 4). Exceptions included the di-
rect VE estimates, which increased through 2009 and then
decreased in 2010, and the total VE estimates, which in-
creased 4-fold from 2007 to 2008.
Absolute benefits of rotavirus vaccination
Under the assumption of perfect sensitivity and specificity
of the RGE ICD-9-CM code, 31–33 RGE hospitalizations
per 10,000 child-years were prevented in vaccinated children,
and 10–26 RGE hospitalizations per 10,000 child-years were
prevented in unvaccinated children in the cohort during each
calendar year from 2007–2010 (among vaccinated children,
6–21 hospitalizations were prevented by direct effects, and
10–26 hospitalizations were prevented by indirect effects)
(Table 5). Considering the total effects in the vaccinated
and indirect effects in the unvaccinated, to prevent 1 RGE
hospitalization in our cohort, 315 (31.8/10,000)−1 to 421
(23.8/10,000)−1 children required a rotavirus vaccination.
Assuming a more realistic scenario of 50% and 25% sensitiv-
ity of the RGE ICD-9-CM code, only 80 (31.8 × 4/10,000)−1
to 210 (23.8 × 2/10,000)−1 children may have required a
rotavirus vaccination to prevent 1 RGE hospitalization. Com-
pared with estimates relying on only RGE diagnostic codes,
those using AGE diagnostic codes to estimate the number of
RGE hospitalizations prevented in our cohort increased the
number by 130%–180% among rotavirus-vaccinated chil-
dren each calendar year (Table 6).
DISCUSSION
RV5 or RV1 was highly effective in preventing RGE hos-
pitalizations in this population of commercially insured US
infants and children aged 8–20 months. Direct VE was
high across each calendar year, and indirect protection
slightly increased the VE among rotavirus-vaccinated chil-
dren. By comparison, in another study that examined RGE
health care utilization in children under 5 years of age from
January to June 2008 and January to June 2009 using the
MarketScan Research Databases, high direct VE of 89%
(95% CI: 79%, 94%) and 89% (95% CI: 84%, 93%) was
also demonstrated (13). In clinical trials, a complete series
(3 doses) of RV5 was 98% (95% CI: 88%, 100%) efficacious
against severe RGE for the first full rotavirus season after vac-
cination among infants primarily in the United States and
Finland, and a complete series (2 doses) of RV1 was 85%
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Figure 4. Diarrhea-related hospitalizations per 10,000 children among commercially insured US infants, 8–20 months of age, in the pre–rotavirus
vaccine period (2001–2005) and rotavirus vaccine period (2007–2010). Solid black line, rotavirus (International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM), code 008.61); small black dashed line, viral excluding rotavirus (ICD-9-CM codes 008.6 and 008.8,
excluding 008.61); large black dashed line, bacterial (ICD-9-CM codes 001–005 and 008.0–008.5, excluding 003.2); hollow dashed line, presumed
infectious (ICD-9-CM codes 009.0–009.3); dotted line, presumed noninfectious (ICD-9-CM code 558.9); dashed and dotted line, diarrhea otherwise
specified (ICD-9-CM code, 787.91).
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for severe RGE from 2 weeks after the second dose until 1
year of age among infants in Latin America (15, 16). Our di-
rect VE estimates were similar to those calculated in the
aforementioned clinical trials, despite the fact that 21% of
the infants in our postmarketing study did not complete a ro-
tavirus vaccine series. In our view, this observation has 2 pos-
sible explanations.
First, partial completion of a rotavirus vaccine series may
still result in high direct VE. This observation has been sup-
ported by other postmarketing studies, including an active,
prospective, population-based case-control study of laboratory-
confirmed RGE hospitalizations and emergency department
visits in 3 US counties from January to June 2006 to January
to June 2009. With rotavirus-negative AGE controls, the di-
rect VEs of RV5 for 1-, 2-, and 3-dose rotavirus vaccine reg-
imens were 74% (95% CI: 37%, 90%), 88% (95% CI: 66%,
96%), and 87% (95% CI: 71%, 94%) in children under 4
years of age (17). Another study that used a database from a
large US health insurer to estimate 1- and 2-dose direct VE
estimates in preventing RGE hospitalizations and emergency
department visits for RV5 during the 2007 and 2008 rotavirus
seasons found similarly high VE (for 1 dose, VE = 88%,
95% CI: 45%, 99%; for 2 doses, VE = 94%, 95% CI: 61%,
100%) (18).
An alternative explanation may be that our direct VE esti-

























































































Figure 5. A) Incidence of acute gastroenteritis (AGE) hospitalizations per 10,000 child-years among commercially insured US infants and chil-
dren, 8–20 months of age, individual years following vaccine introduction (2007–2010) versus prevaccine years combined (2001–2005). Solid line,
2001–2005; dashed and dotted line, 2007; small dashed line, 2008; large dashed line, 2009; dotted line, 2010. B) Incidence of AGE hospitalizations
per 10,000 child-years among commercially insured US infants and children, 8–20 months of age, individual prevaccine years (2001–2005). Solid
line, 2001; dashed and dotted line, 2002; small dashed line, 2003; large dashed line, 2004; dotted line, 2005.
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when a vaccine provides indirect protection, and the percent
vaccinated in subpopulations is not equal (the likely scenario
for most postmarketing studies), then direct VE estimates
may be biased upward from clinical trial efficacy estimates
because the vaccinated subpopulation will receive more indi-
rect protection than the unvaccinated subpopulation (19).
Thus, our direct VE estimates may in fact have included mea-
sures of indirect protection.
We expected indirect or “herd” protection against RGE
hospitalizations to increase with each successive calendar
year from 2007 to 2010, but this was not the case. The calen-
dar year 2009 had a slightly lower indirect VE estimate than
2008 (44% vs. 40%). Although a lack of difference between
these estimates cannot be ruled out given the overlapping
confidence intervals, smaller or total absences of indirect pro-
tection in 1-year-olds in 2009 has been observed in other
studies (11, 13, 20). Although some of these studies used
external rates to estimate rotavirus vaccine coverage, and
thus do not quantify measures of indirect VE, they have hy-
pothesized that the low levels of rotavirus activity during the
2008 season allowed unvaccinated children to pass through
the season without exposure to wild-type virus until 2009
(11, 20). However, because rotavirus activity in the United
States was also curtailed in 2009, and the indirect VE esti-
mate more than doubled to 82% in 2010 in our study, addi-
tional years of follow-up using the MarketScan Research
Databases and other data sources may be needed to better es-
tablish time trends related to the indirect effectiveness of ro-
tavirus vaccination in the United States. Rapid declines of
rotavirus vaccine activity during the study period complicate
the interpretation of the impact of indirect VE.
Compared with 2008 and 2009, in 2010, the more than
3-fold decrease in the direct IRD (despite high direct VE)
and nearly 3-fold increase in the indirect IRD support our
finding that rotavirus circulation was very limited in 2010
(Table 5, Figure 3). In such scenarios, reporting IRDs that in-
corporate impact at the population level (i.e., indirect, total,
and overall) may be important if the objective is to measure
the public health benefit rather than the clinical benefit. For
instance, assuming perfect sensitivity and specificity, if the
direct IRD in 2010 had been used rather than the overall
IRD to calculate the number of children requiring a vaccine
to prevent 1 RGE hospitalization, 1,613 children ((6.2/
10,000)−1) or approximately 4–5 times as many would
need to be vaccinated. From a clinical point of view, this es-
timate may be reasonable (i.e., physicians may be required to
Table 3. Rotavirus Vaccine Effectiveness Estimates Against Rotavirus Gastroenteritis Hospitalizationa in US Commercially Insured Infants and
























2007 51.3 3 68,380 60 64,929 87 58, 96
2008 65.9 23 175,890 91 91,051 87 80, 92
2009 80.3 22 250,035 74 61,218 92 87, 95
2010 85.9 8 254,377 13 41,946 90 75, 96
Indirect effectiveness
2007 51.3 60 64,929 14 −14, 36
2008 65.9 91 91,051 44 30, 55
2009 80.3 74 61,218 40 24, 53
2010 85.9 13 41,946 82 70, 90
Total effectiveness
2007 51.3 3 68,380 91 73, 97
2008 65.9 23 175,890 92 88, 95
2009 80.3 22 250,035 95 92, 97
2010 85.9 8 254,377 98 96, 99
Overall effectiveness
2007 51.3 63 133,309 40 20, 54
2008 65.9 114 266,941 75 69, 79
2009 80.3 96 311,253 83 79, 86
2010 85.9 21 296,323 96 93, 97
Abbreviations: CI, confidence interval; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine.
a During the prevaccine period (2001–2005), there were 722 events among 277,899 children.
b Adjusted for birth month and age using the formula, (1 – hazard ratio) × 100.
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vaccinate a larger number of infants in 2010 compared with
earlier years to prevent 1 RGE hospitalization); however,
such use of the direct IRD in 2010 makes the rotavirus vac-
cine appear to be a less effective public health intervention
when, in reality, the decreased circulation of rotavirus,
which helped to substantially reduce the rate of hospitaliza-
tions in unvaccinated children, should be attributed to the
vaccine, and in our view, accounted for in estimates when
the public health perspective is of primary interest.
Our study has important strengths. First, across both time
and vaccination status, the infants and children in the 5 calen-
dar periods we examined were generally well balanced on se-
lected covariates, which included proxies for health, potential
sources of rotavirus infection, and population-level rotavirus
vaccination coverage and mixing patterns. Because all cohort
members were commercially insured and required to have at
least 1 outpatient claim and at least 1 dose of diphtheria, tet-
anus, and acellular pertussis vaccine during infancy, such in-
clusion criteria may have led to the relatively good balance
between the groups with regard to the measured, and hope-
fully, unmeasured, potential confounders. Second, because
we used Cox proportional hazards regression, our analyses
inherently adjusted for age. We also stratified by year to ac-
count for increasing vaccination coverage, and we adjusted
for month of birth to account for the changing seasonality
of rotavirus over the study period. Further adjustment using
the covariates we described in Table 1 did not appreciably
change our VE estimates (data not shown). This lack of
change was not surprising because the groups seemed well
balanced. Third, baseline rates (in 2001–2005) of RGE hos-
pitalizations used to estimate indirect, total, and overall VE
and corresponding IRDs in our study were the same as base-
line rates from 2002 to 2006 in 1-year-olds in another study
using MarketScan Research Databases (33 per 10,000 child-
years) (13) and were similar to baseline rates from 2000 to
2006 in those aged 12–17 months in a State Inpatient Data-
base study (32 per 10,000 child-years, 95% CI: 25, 40) (11).
This finding was reassuring because 3 of the 4 VE and IRD
measures relied on baseline estimates. Finally, our study pro-
vided some evidence that the decline of RGE hospitalizations
from 2007 to 2010 was due to the rotavirus vaccines and not
another extraneous cause. Figure 4 illustrates a sharp decline
in the proportion of children hospitalized for RGE during the
rotavirus vaccine period; however, proportions of children
hospitalized from other infectious causes of gastroenteritis,
including other viral and bacterial pathogens, remained con-
sistent with pre–rotavirus vaccine years. This would be ex-
pected in the absence of time trends and when the rotavirus
Table 4. Rotavirus Vaccine Effectiveness Estimates Against Acute Gastroenteritis Hospitalizationa in US Commercially Insured Infants and
























2007 51.3 142 68,378 271 64,928 22 3, 37
2008 65.9 413 175,765 317 90,882 40 30, 48
2009 80.3 512 249,838 300 61,136 56 49, 62
2010 85.9 398 254,232 109 41,888 41 27, 53
Indirect effectiveness
2007 51.3 271 64,928 −8 −24, 6
2008 65.9 317 90,882 24 15, 33
2009 80.3 300 61,136 9 −3, 19
2010 85.9 109 41,888 45 33, 54
Total effectiveness
2007 51.3 142 68,378 12 −5, 27
2008 65.9 413 175,765 48 43, 53
2009 80.3 512 249,838 59 54, 62
2010 85.9 398 254,232 65 62, 69
Overall effectiveness
2007 51.3 413 133,306 0 −13, 11
2008 65.9 730 266,647 40 35, 45
2009 80.3 812 310,974 48 44, 52
2010 85.9 507 296,120 62 58, 66
Abbreviations: CI, confidence interval; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine.
a During the prevaccine period (2001–2005), there were 2,021 events among 277,893 children.
b Adjusted for birth month and age using the formula, (1 – hazard ratio) × 100.
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Table 5. Absolute Reduction per 10,000 Child-Years of Rotavirus Gastroenteritis Hospitalizations Prevented by the Rotavirus Vaccination Program in Commercially Insured US Infants and
Children 8–20 Months of Age, 2007–2010a
Calendar Year by
Effectiveness
























2007 3 28,250 1.1 60 37,791 15.9 −14.8 −19.0, −10.6
2008 23 85,452 2.7 91 39,447 23.1 −20.4 −25.2, −15.5
2009 22 131,381 1.7 74 32,292 22.9 −21.2 −26.5, −16.0




2007 60 37,791 15.9 722 216,767 33.3 −17.4 −22.1, −12.7
2008 91 39,447 23.1 722 216,767 33.3 −10.2 −15.6, −4.9
2009 74 32,292 22.9 722 216,767 33.3 −10.4 −16.2, −4.6




2007 3 28,250 1.1 722 216,767 33.3 −32.3 −35.0, −29.5
2008 23 85,452 2.7 722 216,767 33.3 −30.6 −33.3, −28.0
2009 22 131,381 1.7 722 216,767 33.3 −31.6 −34.2, −29.1
2010 8 118,708 0.7 722 216,767 33.3 −32.6 −35.1, −30.2
Overall effectiveness: total
in vaccine year versus
prevaccine periodc
2007 63 66,041 9.5 722 216,767 33.3 −23.8 −27.2, −20.4
2008 114 124,899 9.1 722 216,767 33.3 −24.2 −27.1, −21.2
2009 96 163,673 5.9 722 216,767 33.3 −27.4 −30.1, −24.7
2010 21 137,689 1.5 722 216,767 33.3 −31.8 −34.3, −29.3
Abbreviations: CI, confidence interval; IRD, incidence rate difference.
a Assumes 100% sensitivity and specificity of the rotavirus gastroenteritis diagnostic code.
b Calculated using the formula IR1− IR0.






















































































2007 142 28,209 50.3 271 37,696 71.9 −21.6 −33.5, −9.6
2008 413 85,259 48.4 317 39,319 80.6 −32.2 −42.2, −22.2
2009 512 131,096 39.1 300 32,165 93.3 −54.2 −65.3, −43.1




2007 271 37,696 71.9 2,021 216,117 93.5 −21.6 −31.1, −12.1
2008 317 39,319 80.6 2,021 216,117 93.5 −12.9 −22.7, −3.1
2009 300 32,165 93.3 2,021 216,117 93.5 −0.3 −11.6, 11.1




2007 142 28,209 50.3 2,021 216,117 93.5 −43.2 −52.4, −34.0
2008 413 85,259 48.4 2,021 216,117 93.5 −45.1 −51.3, −38.9
2009 512 131,096 39.1 2,021 216,117 93.5 −54.5 −59.8, −49.2





2007 413 65,905 62.7 2,021 216,117 93.5 −30.9 −38.1, −23.6
2008 730 124,578 58.6 2,021 216,117 93.5 −34.9 −40.8, −29.0
2009 812 163,261 49.7 2,021 216,117 93.5 −43.8 −49.1, −38.5
2010 507 137,452 37.0 2,021 216,117 93.5 −56.6 −61.8, −51.4
Abbreviations: AGE, acute gastroenteritis; CI, confidence interval; IRD, incidence rate difference.
a Assumes 100% sensitivity and specificity of the AGE diagnostic codes.
b Calculated using the formula, IR1− IR0.




































vaccine ICD-9-CM code is specific to RGE. Interestingly, the
proportion of hospitalizations due to presumed noninfectious
diarrhea declined steadily during the rotavirus vaccine pe-
riod, for which reasons are currently unknown.
Our results should be interpreted with caution because of
some limitations. First, the ICD-9-CM code for RGE likely
had low sensitivity, and the sensitivity analyses made as-
sumptions that may not have been entirely realistic, including
that the sensitivity did not vary over time or between vacci-
nated and unvaccinated children, that estimates of 25% and
50% sensitivity were reasonable, and that the specificity of
the RGE ICD-9-CM code was 100% (9, 10, 21). ICD-9-
CM diagnostic codes for AGE were also subject to low sen-
sitivity; a recent study conducted at 3 US children’s hospitals
found that only 52% of children hospitalized with AGE re-
ceived a qualifying diagnostic code at discharge (22). Fortu-
nately, low sensitivity of RGE or AGE ICD-9-CM codes
would not bias VE estimates assuming 100% specificity.
We can assume specificity close to 100% on the basis of a
study conducted at a large US children’s hospital that
found the rotavirus ICD-9-CM code to be 97% specific
(10), and another study showing RGE and AGE hospitaliza-
tion patterns similar to those in our study (11).
Second, we limited follow-up of infants and children to 1
year (8–20 months of age) to minimize bias, because children
enrolled for longer periods may differ with respect to unmea-
sured confounding factors from those enrolled for shorter pe-
riods of time. This restriction may have helped increase the
generalizability of the results for those aged 8–20 months
while decreasing the generalizability to other age groups.
One modeling study and 1 study using a convenience sample
of laboratories suggested that the US rotavirus vaccine pro-
gram may have increased the mean age at which infants
and children are first infected with rotavirus, and thus are po-
tentially hospitalized with RGE (23, 24). Despite this poten-
tial shift, our study would still appropriately document
rotavirus VE among those aged 8–20 months, and because
RGE hospitalizations are generally most serious in very
young children (e.g., <2 years), our study would still have
captured many of the most clinically significant cases.
Third, our study considered infants receiving any number
of doses of rotavirus vaccine as “vaccinated” and did not
compare the direct VE of RV5 with that of RV1 because of
the limited number of infants vaccinated with RV1. A few
comparative effectiveness studies, as well as studies assess-
ing partial rotavirus vaccine effectiveness, have been pub-
lished, and ongoing monitoring should continue to assess
these questions (17, 18, 25–28).
Fourth, our study could not confirm whether more children
tested negative for rotavirus or were less frequently tested
over time because we did not have access to laboratory re-
sults. Based on the US National Respiratory and Enteric
Virus Surveillance System data, rotavirus testing may have
decreased from July 2009 to June 2010 (29). In a study
using these data, the numbers of antigen detection tests per-
formed in 25 consistently reporting laboratories from the
month of July to June of the following year during the periods
2000–2006, 2007–2008, and 2008–2009 were similar, but
from July 2009 to June 2010, the number of tests declined
by approximately 1 quarter to 9,909; however, the proportion
of tests that were positive for rotavirus also declined by ap-
proximately half, from 9.0% and 10.7% in 2007–2008 and
2008–2009, respectively, to 4.6% in 2009–2010 (29). On
the basis of these data, we assumed that, although testing
may have decreased during the last rotavirus season in our
study (in 2010), testing decreased because fewer children pre-
sented as inpatients with potential RGE. Thus, we do not
think that changes in testing policies biased our results.
Finally, our study may have limited generalizability be-
cause it involved only US infants and children with commer-
cial insurance and did not include those with Medicaid
insurance (35% of the US population 0–18 years of age in
2012) or the uninsured population (9% of the US population
0–18 years of age in 2012) (7). Although data are limited, en-
rollment in Medicaid during childhood appears to have been
steady over the last decade, alleviating some concern that
fluctuations over time could further limit the generalizability
and comparability of our cohorts (7, 30). Although direct VE
is less likely to show relevant heterogeneity across US popu-
lations, all measures involving indirect VE would tend to be
population specific.
If a vaccine has high direct VE, such measurements may
only slightly underestimate the total VE because VE cannot
exceed 100%. However, if low circulation of a pathogen is at-
tributed to a vaccine program, failing to consider population-
level VE measures on the absolute scale (e.g., indirect, total,
and overall IRD)may substantially underestimate the sustained
impact of the program on important public health outcomes.
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